# Genryzon Red Flag Monitoring > Red-flag safety scan for a child on Genryzon (somatrogon, weekly long-acting growth hormone) — recognise and act on the treatment-emergent adverse events that require holding, investigating, or stopping the drug. Covers benign intracranial hypertension, slipped capital femoral epiphysis, pancreatitis, injection-site myositis (m-cresol), scoliosis progression, second neoplasm surveillance in cancer survivors, hyperglycaemia unmasking, and adrenal insufficiency unmasking. Use when a clinician asks what side effects to watch for on Genryzon, red flags on weekly GH, headache in a child on somatrogon, limp in a child on GH, abdominal pain on Genryzon, or is following up a paediatric GHD patient on somatrogon. Grounded in the Pfizer India Product Monograph (Genryzon LPD, 2022 — PfLEET 2022-0081166). - Skill: `dromlakhani/genryzon-red-flag-monitoring` (Agent Skill) - Install (CLI): `npx skillmds@latest add dromlakhani/genryzon-red-flag-monitoring` - Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/genryzon-red-flag-monitoring/raw - Safety review: pending (external: skill-scanner PASS, skillspector PASS) - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Marketing & Growth - Author: dromlakhani (https://skillmd.com/u/dromlakhani) - Updated: 2026-09-08 - Page: https://skillmd.com/skills/dromlakhani/genryzon-red-flag-monitoring --- # Genryzon Red-Flag Monitoring Safety net for a child already on somatrogon. Walk this scan at every follow-up visit and any time the family reports a new symptom. --- ## Step 1 — Symptom-triggered scan at every visit Ask the family (and the child directly if age-appropriate) about **each** of the following since the last visit. Any positive → move to the matching Step 2 workup. | Symptom | Suspect | |---|---| | Persistent headache; vision changes; nausea/vomiting; papilloedema | **Benign intracranial hypertension** | | New limp; hip pain; knee pain (referred from hip) | **Slipped capital femoral epiphysis (SCFE)** | | Severe or persistent abdominal pain | **Pancreatitis** | | Localised injection-site myalgia; disproportionate pain at injection sites | **Myositis (m-cresol excipient)** | | Back curvature progression; asymmetry of shoulders/hips; scoliosis on inspection | **Scoliosis progression** | | New neurological symptom in a childhood cancer survivor with prior cranial radiation | **Second neoplasm (esp. meningioma)** | | Polyuria, polydipsia, weight loss, or rising HbA1c | **Somatrogon-induced hyperglycaemia** | | Fatigue, hypotension, weight loss, hypoglycaemia, hyponatraemia | **Unmasked central hypoadrenalism** | | Fatigue, cold intolerance, constipation, poor growth despite therapy | **Unmasked central hypothyroidism** | | New hypersensitivity: rash, angioedema, wheeze, anaphylaxis | **Systemic hypersensitivity** | --- ## Step 2 — Specific workup and immediate action per red flag ### Benign intracranial hypertension (IH) **Workup:** - Fundoscopy — look for papilloedema - Neurological exam - CT/MRI brain to exclude a mass - If exam consistent with IH → LP for opening pressure (per neurology) **Action:** - **Temporarily discontinue somatrogon** - Refer to neurology / neuro-ophthalmology - Restart cautiously **only after resolution**, with close monitoring. There is no consensus rule for restart timing; document the joint decision with neurology ### Slipped capital femoral epiphysis (SCFE) **Workup:** - Urgent hip / knee X-ray (AP and frog-lateral of both hips) - Refer to paediatric orthopaedics **Action:** - **Non-weight-bearing** until orthopaedic review — SCFE can worsen with continued weight-bearing - Somatrogon can generally be continued once SCFE is managed, but discuss with orthopaedic team ### Pancreatitis **Workup:** - Serum lipase and amylase - Ultrasound / CT abdomen if levels elevated or persistent pain - Look for other precipitants (gallstones, hypertriglyceridaemia, drugs) **Action:** - **Hold somatrogon** during acute episode - Standard pancreatitis management (fluids, pain control, NPO if severe) - Restart only after full resolution, with careful monitoring ### Injection-site myositis (m-cresol) **Workup:** - Clinical assessment — disproportionate pain, tenderness, swelling at injection sites - CPK if diffuse myalgia - MRI of affected muscle if severe or persistent **Action:** - **Switch to a metacresol-free growth hormone product** (m-cresol is the preservative in Genryzon) - Local supportive care ### Scoliosis progression **Workup:** - Adam's forward bend test - Standing spinal X-ray (Cobb angle) - Refer to paediatric orthopaedics / spinal team if Cobb ≥20° or rapid progression **Action:** - Somatrogon can generally be continued — GH does not directly cause scoliosis but rapid growth may reveal or worsen it - Manage the scoliosis per orthopaedic protocol (bracing, surgery as indicated) ### Second neoplasm — childhood cancer survivors **Focus on:** - **Cranial radiation history → meningioma** is the most-reported second tumour on GH - **New neurological symptom, headache, cranial nerve deficit, focal deficit** → MRI brain - Any suspicious skin or somatic lump → biopsy per oncology **Action:** - **Loop oncology in early** for any concerning symptom - Adhere to the survivor's baseline surveillance schedule - If second neoplasm is confirmed → **discontinue somatrogon** and manage the neoplasm ### Somatrogon-induced hyperglycaemia **Workup:** - Fasting plasma glucose + HbA1c - OGTT if borderline **Action:** - **Diabetes at diagnosis** → involve paediatric diabetologist; escalate insulin/OAD as needed. Somatrogon can usually continue but with tight glucose monitoring - **Pre-diabetes** → lifestyle intensification, monitor more frequently - **Insulin-treated child already** → up-titrate insulin doses as needed ### Unmasked central hypoadrenalism **Workup:** - Morning cortisol - ACTH stimulation test / ITT if borderline **Action:** - **If adrenal crisis suspected → treat as adrenal crisis first**: IV hydrocortisone, IV fluids, glucose. Investigate afterwards - **If confirmed central hypoadrenalism** → start (or escalate) hydrocortisone replacement. Continue somatrogon - **If child already on hydrocortisone replacement** → dose may need to be **increased** on GH (GH ↓ cortisone→cortisol conversion) ### Unmasked central hypothyroidism **Workup:** - TSH + free T4 (interpret carefully — in central hypothyroidism, TSH may be normal or inappropriately low despite low fT4) **Action:** - **Start or up-titrate levothyroxine** — untreated hypothyroidism blunts response to GH - Recheck TFTs 6–8 weeks after any thyroxine change ### Systemic hypersensitivity **Action:** - **Immediately discontinue Genryzon** - Standard anaphylaxis management (adrenaline IM, airway support, IV fluids, corticosteroids, antihistamines) - **Do not rechallenge** — switch to a somatrogon-free growth hormone product after specialist review --- ## Step 3 — Scheduled monitoring at every 6–12 month visit (more often in puberty) Even without new symptoms, at each planned visit check: - **Auxology:** height, weight, height velocity (cm/yr), BMI - **Bone age** — annually or as indicated - **Tanner stage** - **IGF-1** (day 4 post-dose — see `genryzon-igf1-titration`) - **TSH + free T4** - **Fasting glucose ± HbA1c** - **Fundoscopy** if any suspicious symptom - **Spinal inspection** for scoliosis - **Pubertal progression** and, in girls, review of oral estrogen / OCP use --- ## Guardrails - **Headache in a child on somatrogon is intracranial hypertension until proven otherwise** — do not attribute to common causes without a fundoscopy - **Any limp or hip/knee pain in a child on GH warrants a same-week hip X-ray for SCFE** — this diagnosis is regularly missed and delayed diagnosis worsens the outcome - **Injection-site myalgia is not "normal soreness"** — it can be m-cresol myositis and mandates a switch of GH product - **Childhood cancer survivors on GH need active surveillance for second neoplasm** — a neurological complaint is never "just growing pains" in this group - **Adrenal crisis can present as vague fatigue and abdominal pain** — a low threshold for morning cortisol / stress-dose steroids in any child on GH who becomes unwell - **Never dismiss papilloedema on baseline fundus and continue GH** — that's a signal that pre-existing IH was missed and now the drug will worsen it - **Somatrogon does not need to be permanently stopped for most of these events** — most can be resumed after the underlying issue is addressed, except confirmed second neoplasm and severe hypersensitivity, which are absolute stops --- ## Related MD2SKILL skills - `genryzon-prescribing-guide` — starting dose, injection technique, monitoring cadence - `genryzon-igf1-titration` — how to interpret and act on IGF-1 SDS - `genryzon-pretreatment-screening` — baseline work-up before first dose - `genryzon-drug-interactions` — glucocorticoid, insulin, thyroxine, oral estrogen adjustments - `genryzon-treatment-discontinuation` — when to stop growth hormone entirely --- ## Source Pfizer Products India Pvt. Ltd. **GENRYZON® (Somatrogon) Solution for Injection in Pre-filled Pen — Prescribing Information (India).** LPD version 2022-0081166 (PfLEET 2022-0081166). Section 4.4 "Special Warnings and Precautions for Use" and Section 4.8 "Undesirable Effects".